DelveInsight’s “Psoriatic Arthritis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Psoriatic Arthritis pipeline landscapes. It comprises Psoriatic Arthritis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Psoriatic Arthritis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Psoriatic Arthritis pipeline products.
Some of the key takeaways of the Psoriatic Arthritis Pipeline Report
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as AbbVie, Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Pfizer, etc., are developing therapies for the treatment of Psoriatic Arthritis.
Emerging therapies such as Skyrizi and Rinvoq, Ilumya, Deucravacitinib, Bimekizumab, Brepocitinib, are expected to have a significant impact on the Psoriatic Arthritis market in the coming years.
Get an overview of pipeline landscape @ Psoriatic Arthritis Clinical Trials Analysis
Psoriatic Arthritis Overview
Psoriatic Arthritis is a sort of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but joint problems can sometimes begin before skin patches appear.
Psoriatic Arthritis Emerging Drugs
Skyrizi and Rinvoq by AbbVie
Ilumya by Sun Pharma
Deucravacitinib by Bristol-Myers Squibb
Bimekizumab by UCB Biopharma
Brepocitinib by Pfizer
And others.
For further information, refer to the detailed report @ Psoriatic Arthritis Pipeline Therapeutics
Scope of Psoriatic Arthritis Pipeline Drug Insight
Coverage: Global
Major Players: AbbVie, Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Pfizer, and others.
Pipeline Therapies: Skyrizi and Rinvoq, Ilumya, Deucravacitinib, Bimekizumab, Brepocitinib, and others.
Table of Contents
1
Psoriatic Arthritis Report Introduction
2
Psoriatic Arthritis Executive Summary
3
4
Psoriatic Arthritis- Analytical Perspective In-depth Commercial Assessment
5
Psoriatic Arthritis Pipeline Therapeutics
6
Psoriatic Arthritis Late Stage Products (Phase II/III)
7
Psoriatic Arthritis Mid Stage Products (Phase II)
8
Psoriatic Arthritis Early Stage Products (Phase I)
9
Psoriatic Arthritis Preclinical Stage Products
10
Psoriatic Arthritis Therapeutic Assessment
11
Psoriatic Arthritis Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Psoriatic Arthritis Key Companies
14
Psoriatic Arthritis Key Products
15
Psoriatic Arthritis Unmet Needs
16
Psoriatic Arthritis Market Drivers and Barriers
17
Psoriatic Arthritis Future Perspectives and Conclusion
18
Psoriatic Arthritis Analyst Views
19
Appendix
20
About DelveInsight
Get a customized pipeline report @ Psoriatic Arthritis Drugs Pipeline Report
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/